Bezafibrate: Uses, Dosage, Side Effects, and More

Introduction to Bezafibrate

Bezafibrate is a lipid-lowering agent used to treat hyperlipidaemia. It belongs to the fibrate class of drugs and has been a mainstay in the management of dyslipidaemia for many years. Bezafibrate works by reducing LDL cholesterol and triglyceride levels in the blood while increasing HDL cholesterol.

Chemical Composition and Structure

Bezafibrate has the chemical formula C ₁₉H ₂₀ClNO ₄. It is structurally related to other fibrates like clofibrate. The presence of a chlorine atom in its structure distinguishes it from other fibric acid derivatives.

Pharmacodynamics

Bezafibrate acts by interacting with peroxisome proliferator-activated receptors (PPARs), particularly PPARα. This interaction leads to transcriptional activation of genes involved in lipid metabolism, resulting in decreased synthesis and increased hepatic clearance of triglycerides.

Pharmacokinetics

After oral administration, bezafibrate is rapidly absorbed from the gastrointestinal tract. It is extensively bound to plasma proteins and has a half-life of 1-2 hours. The drug is metabolized in the liver and excreted primarily in the urine. The usual dosage is 200 mg three times daily or 400 mg once daily.

Clinical Uses

Bezafibrate is used in the treatment of primary and secondary dyslipidaemia, particularly in patients with hypertriglyceridemia. It is also used in the management of combined hyperlipidaemia when statins are not tolerated or are contraindicated.

Efficacy

Clinical trials have demonstrated the efficacy of bezafibrate in reducing LDL cholesterol and triglycerides while increasing HDL cholesterol. In a study by Elkeles et al., bezafibrate significantly reduced plasma triglyceride levels and increased HDL cholesterol in patients with type 2 diabetes.

Safety and Tolerability

Bezafibrate is generally well-tolerated. Common side effects include gastrointestinal disturbances, muscle problems, and kidney issues. Severe side effects are rare but may include rhabdomyolysis and acute renal failure. Bezafibrate should be used with caution in patients with kidney dysfunction.

Drug Interactions

Bezafibrate may interact with other lipid-lowering agents like statins and fibrates, increasing the risk of side effects. It may also interact with anticoagulants, increasing the risk of bleeding. Concomitant use of bezafibrate with repaglinide may increase the risk of hypoglycemia.

Patient Considerations

Bezafibrate is particularly useful in patients with coronary artery disease (CAD) and hypertriglyceridemia. It has also shown therapeutic benefit in special populations like patients with Barth syndrome. Regular monitoring of lipid profile and kidney function is recommended during bezafibrate therapy.

Warnings and Precautions

Patients on bezafibrate should be advised to report any unexplained muscle pain, tenderness, or weakness. Bezafibrate should be discontinued if myopathy is suspected or creatine kinase levels are markedly elevated. Kidney function should be monitored periodically, especially in patients with pre-existing renal impairment.

Contraindications

Bezafibrate is contraindicated in patients with severe hepatic or renal impairment, pre-existing gallbladder disease, and hypersensitivity to the drug or any of its components. It should not be used during pregnancy unless clearly needed.

Side Effects and Adverse Reactions

The most common side effects of bezafibrate include gastrointestinal disturbances (nausea, diarrhea, flatulence), muscle problems (myalgia, weakness), and headache. Severe adverse reactions like rhabdomyolysis, hepatitis, and acute renal failure have been reported rarely.

Dosage and Administration

The recommended dosage of bezafibrate is 200 mg three times daily or 400 mg once daily. The dosage may need to be adjusted in patients with renal impairment. Bezafibrate should be taken with meals to enhance its absorption.

Experimental and Investigational Uses

Bezafibrate is an investigational drug in the United States. It has been granted orphan designation by the FDA for the treatment of Barth syndrome, a rare genetic disorder characterized by cardiomyopathy, skeletal muscle weakness, and neutropenia.

Comparative Effectiveness

Studies have compared the effectiveness of bezafibrate with other fibrates like gemfibrozil and fenofibrate. In a meta-analysis by Jun et al., bezafibrate and fenofibrate showed similar efficacy in reducing triglycerides and increasing HDL cholesterol.

Mechanism Research

Research has elucidated the role of bezafibrate in PPAR agonism. Bezafibrate binds to and transcriptionally activates PPARβ with an EC50 of 50 μM. This activation is thought to mediate some of the lipid-modifying effects of bezafibrate.

Commercial Availability

Bezafibrate is marketed under various brand names including Bezalip, Bezatol, and Bezafibrat. It is available as tablets and sustained-release formulations. Bezafibrate is manufactured by several pharmaceutical companies worldwide.

Conclusion

Bezafibrate is an effective lipid-lowering agent used in the management of dyslipidaemia. Its unique mechanism of action, favourable safety profile, and potential for use in special populations make it a valuable addition to the therapeutic armamentarium. Ongoing research continues to unravel new facets of this drug and expand its clinical applications.

References

1. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21(4):641-648. doi:10.2337/diacare.21.4.641
2. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875-1884. doi:10.1016/S0140-6736(10)60656-3
3. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med. 2009;360(8):838-840. doi:10.1056/NEJMc0806334